Oct 31, 2023· Comment from Association for Accessible Medicines (AAM)· FDA-2023-D-3370-0004
FDA, Please find attached comments from The Association for Accessible Medicines (AAM) regarding Docket No. FDA–2023–D–3370, "Post-Warning Letter Meetings Under the Generic Drug User Fee Act; Guidance for Industry" Thanks, Scott Kuzner, Ph.D., Senior Director, Sciences and Regulatory Affairs Association for Accessible Medicines